Obesity / Weight Management
CagriSema (REDEFINE program)
Investigational fixed-dose combination of cagrilintide and semaglutide for chronic weight management, evaluating efficacy and safety in adults with overweight or obesity.
EndoTrials Clinical Research Center · La Mesa, California
Open clinical studies
Studies currently recruiting at EndoTrials. The list changes as studies open and close. Contact the research team to be considered for these or future studies.
Graves' Disease
GenSci098 (YB-101)
Investigational biologic for the treatment of Graves' disease, evaluating disease control and safety as an alternative to current standard therapy.
Endocrine / Metabolic
REIMAGINE-4
Clinical study within the REIMAGINE program evaluating an investigational therapy for metabolic disease. See the registry link for full design and eligibility.
Type 2 Diabetes
Zenagamtide vs. Semaglutide (AMBITION 3)
Study of once-weekly zenagamtide injection compared with higher-dose once-weekly semaglutide in adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both.
Type 2 Diabetes
Zenagamtide Tablets vs. Placebo (AMBITION 8)
Study of oral zenagamtide tablets compared with placebo in adults with type 2 diabetes treated with metformin, an SGLT2 inhibitor, or both.
Obesity / Weight Maintenance
Tirzepatide-to-Brenipatide Switch (GZMX)
For adults who have maintained weight loss on once-weekly tirzepatide (10 mg): a study of whether switching to once-monthly brenipatide maintains that weight loss, and whether the switch is safe.
One San Diego endocrine group, specialized centers: Diabetes & Endocrine Specialists · SanDiEndo — Interventional Endocrinology · MenoExperts — Menopause & Midlife · HashiExperts — Hashimoto's Care · EndoTrials — Clinical Research